Screener
Aurinia Pharmaceuticals AUPH Compensation and benefits
Compensation and benefits at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:16 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001600620-26-000062
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and development | $1,310 | $335 | $1,421 | $428 |
| Selling, general and administrative | 1,234 | 4,877 | 31 | 1,364 |
| Capitalized in inventory, net | 295 | 228 | 521 | 239 |
| Share-based compensation expense | $2,839 | $5,440 | $1,973 | $2,031 |
Item 1. Financial Statements.
FAQ
- What is Aurinia Pharmaceuticals's compensation and benefits?
- Aurinia Pharmaceuticals (AUPH) reported compensation and benefits of $1.31M in Q2 2026.
- What does compensation and benefits mean?
- Total employee-related costs including salaries, wages, bonuses, commissions, stock-based compensation, health insurance, retirement contributions, and payroll taxes.
Ask your AI about Aurinia Pharmaceuticals's compensation and benefits.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude